USPTO serial 79253337
DUOHEXABODY
Reviewed by CopyMark Law Group
Reg. 5993053Status 707Registered
- Filing date
- Status date
- Registration date
- Feb 25, 2020
- Examiner
- CAPSHAW, DANIEL
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with DUOHEXABODY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Max Vern
Max Vern AMSTER, ROTHSTEIN & EBENSTEIN LLP405 Lexington AvenueNew York, NY 10174United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Chemical, biochemical, biological, and biotechnological preparations, namely, antibodies, bi- and multispecific antibodies as well as antibody fragments, including monovalent antibodies, and derivatives or conjugates of any of these, for in vitro and in vivo scientific and industrial research and development with regard to diseases; Active chemical ingredients for use in the manufacture of pharmaceuticals ] | SECTION 71 - CANCELLED | — |
| 005 | [ Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations based on antibodies, bi- and multispecific antibodies as well as antibody fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases ] | SECTION 71 - CANCELLED | — |
| 042 | Medical, scientific and biological research, especially research into antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these and development of pharmaceutical products based on antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these; chemical analysis; computer programming, namely, programming of computers for the collection and processing of medical data in medical scientific research, development and therapy, including scientific research, development and therapy with antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these | ACTIVE | — |
| 045 | [ Legal services in the field of patent exploitation, namely, patent consultation, patent licensing, and providing information about patent rights; licensing of intellectual property in the field of medicine ] | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Genmab Holding B.V.
- Other trademarks owned by Genmab B.V.
- Other trademarks owned by Genmab Holding B.V.
- Other trademarks owned by Genmab Holding B.V.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named DUOHEXABODY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 24, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 10, 2026 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Aug 4, 2026 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Aug 4, 2026 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Jun 16, 2026 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Jun 16, 2026 | 71.P | REGISTERED - PARTIAL SEC 71 ACCEPTED | — |
| Jun 15, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 5, 2026 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Mar 5, 2026 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Feb 24, 2026 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Apr 24, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 25, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 5, 2024 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jun 5, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 5, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 5, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 5, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 5, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 10, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 22, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 22, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 25, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 25, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 10, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 10, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 20, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 5, 2019 | ALIE | ASSIGNED TO LIE | — |
| Oct 31, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 31, 2019 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Sep 19, 2019 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Sep 13, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Sep 13, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Sep 13, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 5, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 5, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 5, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 6, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 20, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 20, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 12, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 8, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 7, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 6, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 28, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |